

RELIABILITY OF TRANSCUTANEOUS CARBON DIOXIDE MONITORING IN PREMATURE INFANTS WITH CHRONIC LUNG DISEASE

J L Chow
G J Kost
M A Kenny

Department of Laboratory Medicine
University Hospital
University of Washington School of Medicine
Seattle
Washington 98195

J L Chow, BS, BA
Research Associate

M A Kenny, PhD
Professor

Clinical Chemistry Division
Director of Medicine
University of California, Davis
California 95616

G J Kost, MD, PhD

Correspondence to:
John L Chow, BS, BA
3453 MS1A Medical Pathology
University of California, Davis
Davis, California 95616

SYNOPSIS

We studied 15 premature infants with chronic lung disease (CLD) to evaluate the reliability of using transcutaneous CO₂ (tc PCO₂) measurements in estimating arterial CO₂ (PaCO₂) values. The regression equations between tc PCO₂ (Y) and PaCO₂ (X) were $Y = 0.97 + (1.78)(X)$ (torr) with $r = 0.86$ and $S_{y.x} = 13.7$ torr, and $Y = 2.93 + (1.73)(X)$ (torr) with $r = 0.84$ and $S_{y.x} = 15.6$ torr for comparisons of 160 arterial samples and 87 capillary samples, respectively. We identified isolated deviant points from serial tc PCO₂ and PaCO₂ comparisons. This, together with the observed systematic fluctuations of tc PCO₂ relationship over protracted intervals accounted for the large scatter in the regression data. For the 7 CLD infants studied in time series analysis, there were 5.2 and 6.3% probabilities that this was a random phenomena for two cases. Technical errors or single physiological changes were not associated with these observations. We concluded that tc PCO₂ monitoring is clinically useful in following short-term trends of changing CO₂ status in CLD infants. However, the large scatter in our regression data would preclude using the regression equation to estimate PaCO₂ from measured tc PCO₂ in these patients.

INTRODUCTION

Infants with chronic lung disease or bronchopulmonary dysplasia (BPD) are prime candidates for extensive transcutaneous CO₂ monitoring. Hypercarbia, which develops during passive oxygenation of patients with pulmonary edema, during assisted ventilation of those with refractory hypoxia, during weaning from

assisted ventilation, and during apneic episodes, is a frequent problem in such patients but may not be adequately predicted from the combination of transcutaneous O₂ (tc PO₂) monitoring and arterial blood gases (1). Moreover, acceptance of tc PCO₂ monitoring generally is encouraged by the strong correspondence between PaCO₂ and tc PCO₂ measurements [reported *r* values for PaCO₂ and tc PCO₂ comparisons in newborn populations range from 0.79 to 0.98 (2)], the associated conservation of patient blood, relative absence of risk, convenience, and continuous nature of tc PCO₂ data. On the negative side, most reports describe tc PCO₂ values as 1.3 to 1.4 times greater than PaCO₂ values, so that clinician must a) decide tc PCO₂ information is unique, requiring independent interpretation or b) develop schemes for estimating PaCO₂ from tc PCO₂ values. Tremper equate tc PCO₂ and PaCO₂ provided temperature and calibration biases are taken into account (2,4). Alternately, Brunstler et al. (5) and others (6,7) have suggested that the tc PCO₂ instrument display be adjusted to PaCO₂-like values termed "estimated PaCO₂" or "adjusted to PCO₂" based on the equation:

$$\text{adjusted tc PCO}_2 = \frac{\text{measured tc PCO}_2 - \text{intercept}}{\text{slope}}$$

where the slope and intercept are derived from regression analysis of PaCO₂ and tc PCO₂ determinations on a population of premature and term infants with mixed diagnoses.

We decided to retrospectively evaluate the reliability of tc PCO₂ as an estimate of PaCO₂ and as a trend monitor of chronic lung diseased patients during the course of their therapy. We compared the regression analysis of their tc PCO₂ with blood CO₂ tensions in both arterial and capillary specimens. We questioned how "estimated PaCO₂" data based on regression analysis from a mixed newborn population compared with measured blood CO₂ tension during long-term therapy of these infants. Our findings are described in this report.

METHODS AND MATERIALS

Subjects of the study (*n* = 15) were all premature, sick infants diagnosed as having bronchopulmonary dysplasia. They were treated in the Neonatal Intensive Care Unit of University Hospital during an eight-month interval and had arterial and capillary blood gas determinations performed as part of their routine management. Although all were being treated for BPD, they had a spectrum of concurrent pathologies, including anemia, sepsis, hypoglycemia, patent ductus arteriosus, intracranial hemorrhage (Grade IV), seizures, hyperbilirubinemia, and hypocalcemia. The average gestational age was 29 ± 3 wk (*X* ± SD). The average birth weight was 1053 ± 361 g. Ventilator regulation and FIO₂ adjustments for the infants studied were based on PaCO₂, PaO₂, and tc PO₂ measurements.

One hundred acutely ill premature newborns (including the 15 subjects who later developed BPD) formed the reference group whose tc PCO₂ and PaCO₂ comparisons were used to derive the population regression data with which to calculate "estimated PaCO₂" values on BPD infants. Diagnosis for the reference group patients was diverse but most had hyaline membrane disease. For regression analysis, we used only one randomly selected transcutaneous and blood CO₂ tension comparison made on each infant. This reference group's least squares regression relationship between tc PCO₂ (*Y*) and PaCO₂ (*X*) was: $Y = -2.8 + (1.86)(X)$ (torr), *r* = 0.86, and *S*_{*y,x*} = 12.9

torr as reported elsewhere (8).

Sixteen acutely ill premature neonates without diagnosed BPD who received tc PCO₂ for routine management constituted the control group for the randomness time series analysis (9). PaCO₂ and tc PCO₂ comparisons (*n* = 39) from the control group were limited to one set per day every third day for each infant. Three or fewer comparisons per infant were used. The interval studied was 23 d. These comparisons were "random". They demonstrated that any time dependent instrument, operator, or other method related factors did not account for the time series findings with the BPD patient data.

We determined tc PCO₂ with three different carbon dioxide monitors of the same design (model TCM 20, Radiometer America Inc., Cleveland, OH 44145). Two point calibrations were performed at the beginning of each monitoring session with dry CO₂ standard gases (5% and 10% CO₂ in N₂). In vivo drift was determined at the end of each monitoring session. The maximum allowable drift was 4 torr. Calibrations and patient measurements were made with the electrode temperature at 44°C. Heater power and tc PCO₂ measurements were recorded by an external recorder.

We determined blood gases in duplicate on two blood gas analyzers (Model 813, Instrumentation Laboratory, Inc., Lexington, MA 02173). Standard assay protocols and quality control routines were used (10). Imprecision of PaCO₂ measurements as determined by analysis of tonometered blood or commercial control solutions is approximately 3% CV (11).

For BPD patients, a total of 247 blood gas measurements (160 by arterial sample and 87 by capillary sample) were compared with tc PCO₂ concurrently monitored. The arterial blood samples were collected from umbilical, radial or dorsalis pedis arteries. Capillary blood samples were collected from the heel area according to standard protocol. The term PaCO₂ will be used for blood CO₂ tensions in either arterial and capillary specimens throughout this report unless noted otherwise. Temperature corrections were not made on either transcutaneous or blood gas data.

There were 221 separate tc PCO₂ monitoring sessions on the BPD patients. The mean duration per session was about 3 h (range: about 1 to 5 h). Transcutaneous PCO₂ electrodes were placed on the shoulder, chest, abdomen or thigh.

Electrode placement site, monitoring duration, quality control and calibration data for blood gas analyzers and monitors, drift, patient information and patient respiratory therapy were recorded, analyzed and reviewed for significance.

RESULTS

To evaluate how reliably tc PCO₂ could be used as an estimate of PaCO₂ in chronic lung disease patients, we reviewed 1) the regression relationship of tc PCO₂ and PaCO₂ segmented into arterial and capillary groups; 2) the relative agreement of serial tc PCO₂ in the seven infants most frequently monitored during this study; and 3) the distribution of PaCO₂: tc PCO₂ ratios for paired measurements.

Table 1 shows the regression analysis of arterial and capillary blood PaCO₂ with concurrently measured transcutaneous CO₂ tensions. The measurements were all accepted as valid; i.e., no quality control deviations were apparent to technologists or nurses working with the patients or instruments.

The serial simultaneous tc PCO₂ and PaCO₂ determinations on the two most frequently monitored infants are plotted in Figures 1A and 1B. The tc PCO₂




Figure 1
 Transcutaneous PCO₂ and blood PCO₂ comparisons made on two chronic lung diseased premature infants (patients A and B) plotted in time sequence by day. Arterial blood specimens are noted with (O); capillary blood specimens with (Δ). The three most unusual comparisons for each patient are labeled a, b and c.

TABLE 1: REGRESSION OF ARTERIAL AND CAPILLARY BLOOD PaCO₂ WITH CONCURRENTLY MEASURED TC PCO₂ TENSIONS IN PREMATURE INFANTS WITH CHRONIC LUNG DISEASE¹

	BLOOD SAMPLE	
	Arterial	Capillary
n:	160	87
Regression line	tc PCO ₂ = 0.97 + 1.78 (PaCO ₂)	tc PCO ₂ = 2.93 + 1.73 (PaCO ₂)
r:	0.86	0.84
Standard deviation of Intercept	4.0 torr	7.1 torr
Sy.x	13.7 torr	15.6 torr
Observed tc PCO ₂ range	38 — 169 torr	48 — 160 torr
Observed PaCO ₂ range	20 — 93 torr	31 — 87 torr
Mean tc PCO ₂	83 torr	102 torr
Mean PaCO ₂	46 torr	58 torr
Mean of ratios PaCO ₂ /tc PCO ₂	0.57	0.58

¹Fifteen Infants were studied

blood PCO₂ difference (Δ CO₂, or tc: blood bias) showed a gaussian distribution for these patients. For patient A, Figure 1, the CO₂ = 59 ± 18 torr (\bar{X} ± SD). For patient B of that figure, the CO₂ = 32 ± 14 torr. No reason was found to disregard any of the extreme positive or negative values. The extremes of Δ CO₂ (e.g. sets marked a, b and c) were not statistically associated with the fluctuations in patient body temperature, hematocrit, coincident arterial pH, PaO₂, FIO₂, the presence or absence of forced ventilation, patient age, sex or weight. Of the six comparisons labeled (a), (b), or (c) in Figure 1, four were made with abdominal tc electrode placement. Concurrent heater power tracings were not remarkable indicating tissue perfusion was unperturbed and probe attachment satisfactory. The duplication of blood gas analyses, specimen integrity notes, calibration, maintenance, and other control data were consistent with acceptable test performance. The transcutaneous measurement drift in vivo was less than 4 torr in each instance.

To evaluate the long-term reliability of tc PCO₂ for estimating PaCO₂ in individual CLD patients, we examined the data from the seven most frequently monitored CLD patients. We calculated the difference between "estimated PaCO₂" and observed PaCO₂, where "estimated PaCO₂" was derived by inserting the observed tc PCO₂ value in the regression equation for the NICU population in general i.e. tc PCO₂ = -2.8 + (1.86) (PaCO₂) (8). Figures 2A and 2B illustrate the differences for the same infants whose data are shown in Figure 1. Of the 54 comparisons for infant A, 31% were

different by more than 10 torr. Of the 61 comparisons for infant B, only 8% were different by more than 10 torr. The estimates were more likely to be high for infant A while most were low for infant B.

The influence of time on these matched comparisons was examined. For 2 of 7 the patients, the sequential estimated PaCO₂ values deviated from observed PaCO₂ with a unidirectional bias for protracted intervals. The probability that these single direction deviations could be random were only 5.2 and 6.3% for the two worst cases. The other 5 on whom there were enough comparisons for valid statistical analysis were as random as the control group. Figures 1A and 2A illustrate a random series of tc PCO₂ and PaCO₂ observations and of differences between estimated PaCO₂ and corresponding PaCO₂. Figures 1B and 2B illustrate a series with 6.3% probability of being random. In it there are more low estimates of PaCO₂ from day 15 through day 26 than at other times in the series.

Figure 3 shows the frequency distribution of the PaCO₂: tc PCO₂ ratio for all comparisons (n = 247) on the 15 infants with chronic lung disease. The group distribution of ratios was 0.57 ± 0.10 (\bar{X} ± SD). The PaCO₂: tc PCO₂ ratios for the infants A and B in Figure 1 were 0.54 ± 0.09 and 0.59 ± 0.11 respectively. They have representative means and precision for the individual data sets. Among all comparisons there are 6 extreme sets with ratios > 0.8. These extremes are derived from measurements on 5 infants.




Figure 2 Time series representation of the deviation of estimated PaCO₂ from observed PaCO₂ on two chronic lung diseased premature infants (patients A and B) over protracted time periods. Points a, b and c denote three extreme deviants of PaCO₂ estimation in each patient. See also Figure 1.




Figure 3
Frequency distribution of PaCO₂ to tc PCO₂ ratios in fifteen chronic lung diseased patients from 247 simultaneous measurements.

DISCUSSION

Most correlations of PaCO₂ with tc PCO₂ reported in the literature for mixed newborn populations are comparable to our finding with arterial or capillary specimens from chronic lung diseased infants ($r = 0.86$ and 0.84 , respectively). Hazinski and Severinghaus cited 15 clinical trials of transcutaneous PCO₂ sensors with correlations coefficients of $0.80 - 0.98$ (2). The y-intercepts and slopes of reported regression equations vary greatly as might be expected among studies using different patient populations and instruments. Again, our data are not remarkable. Transcutaneous CO₂ tensions are generally greater than blood tensions because heat increases local skin metabolism about $7\%/^{\circ}\text{C}$ to produce more CO₂ and raises the anaerobic temperature coefficient of blood PCO₂ by about $4.5\%/^{\circ}\text{C}$. However, it is interesting that the regression equations reported here are not significantly different from our observations on a mixed population of acutely ill premature newborns made under the same circumstances of NICU operation in this institution (12). This suggests that for transcutaneous PCO₂ measurements infants with chronic lung disease need not be considered separately from the general NICU population.

However, the standard error of the estimates reported here as 13.7 torr and 15.6 torr, for arterial and capillary specimens respectively, are large. Scatter in

regression studies has not been generally quantitated in clinical evaluations. Only values reported for newborns are 6.3 torr (13) 6.2 torr (7) and 4.2 torr (5). As there is no difference between the data for the two specimen types here, blood collection probably did not contribute to this scatter. Moreover, our measurements are well controlled in that our blood gas instruments do not have a capillary versus macro sampling bias, blood gas analyses are duplicated to confirm results, our staffs are continuously indoctrinated to note exact times of blood sampling and blood analysis, electrode drift is within the acceptable limits, and the strip chart recorders continuously monitor heater power and tc PCO₂ etc. Thus the technical factors contributing imprecision to this study were limited. We believe that it is representative of the tc PCO₂ and PaCO₂ comparisons likely to be made for daily care in a tertiary hospital's NICU.

Figures 1 and 2 reinforce the suggestion that the wide confidence intervals about our regression lines accurately reflect tissue and blood CO₂ tension status in a sick premature population where weaning is the major use of monitoring. First, there were transient intervals of non-randomness in the tc PCO₂ to PaCO₂ relationship measured. This may be expected in a typical neonatal intensive care setting. Bhat et al reported that the ΔCO_2 (tc PCO₂ - PaCO₂) in infants was effected by hypoxia and acidosis but not blood pressures so long as they were above 30 mmHg (14).

Tremper et al (3) reported that the Δ CO₂ among adults in shock, defined by a cardiac index < 1.5 L/min.M², averaged 61 torr compared with 23 torr for hemodynamically stable patients. Brunstler et al found that only systolic blood pressures below 15 mmHg was consistently associated with deviant transcutaneous and blood comparisons (n = 76) on 24 infants, 23 of whom were mechanically ventilated (5). In their experience, body temperature (33.5–38.1°C), hematocrit (28–65%), and pH (6.89 to 7.61 units) were not implicated. In their regression study the standard error of the estimate was 4.15 torr. (excluding data derived on patients with low blood pressure) Finally, the existence of variable tc PCO₂: PaCO₂ relationships specifically in chronic lung disease infants is suggested by Philip who quotes Peabody as reporting that infants with bronchopulmonary dysplasia may require a correction factor (e.g. 2.0) which is different from other children's (e.g. 1.3 or 1.4) (15). While we believe intervals of hypoxia, acidosis, edema, anemia, and/or hypermetabolic states might account for the transient deviant blood and transcutaneous comparisons we described, regression analysis failed to statistically identify a single explanation. Moreover, our patients were in physiological disequilibrium as they were almost all undergoing mechanical ventilation at the time of data collection. There may be transient tissue CO₂ build up associated with incomplete tissue washout (16) or lung inefficiency.

A second explanation of our regression data scatter is also illustrated in the serial plots of figures 1 and 2 as major isolated deviations (e.g. points a, b and c). Hazinski and Severinghaus had noted the occurrence of "single extreme and deviant points" in several published studies but considered them atypical and suggested that they could be eliminated from performance data evaluations (2). We agree that this type of observation does not reflect instrument performance but consider it the outcome of physiological phenomena. In a working NICU, we believe such "poor" tc PCO₂ correlations with PaCO₂ should be expected by virtue of the patient clientele.

Several authors (5,6,7) suggested that regression equations for matched tc PCO₂ and PaCO₂ comparisons be used to derive "estimated PaCO₂" (or "adjusting tc PCO₂") values from measured tc PCO₂. Adjusting instrument output with this kind of *in vivo* calibration is attractive as it would circumvent inevitable clinician confusion in dealing with the two gas tension values simultaneously. Figure 2 demonstrates that the incidence of "poor" PaCO₂ estimations varies among patients. The frequency of estimate errors greater than 10 torr for infant A was 31%. This argues against using such system for automatic PaCO₂ estimation, because it is impossible to screen out inappropriate infants when we do not fully understand the precipitating phenomena. Secondly, the magnitude of exceptional residuals (to +33 torr) illustrated by points a, b and c in series of Figure 2 also suggests a grave clinical hazard in *in vivo* calibration. Finally, the time dependent shift in quality of PaCO₂ estimates on a given baby cannot be dealt with in a working NICU unless the physiological causes of poor correlation are taken into account. In our population, the observed scatter in the regression studies precludes using tc PCO₂ to estimate PaCO₂. For example, a measured tc PCO₂ of 83 torr would correspond to estimated PaCO₂ values between 33 and 59 torr using the prediction bands with 95% confidence for the regression equation $tc\ PCO_2 = 0.97 + (1.78)(PaCO_2)$.

The time series analysis was done to demonstrate the pitfall of relying on tc PCO₂ measurements for too precise an estimate of PaCO₂ in CLD patients and/or the inaccuracy of assuming a simple CO₂ can be used

to estimate PaCO₂ for very long. The lack of randomness in the time series also suggests that unidentified physiological events which may last for several days are influencing the predictability of blood PCO₂ from transcutaneous PCO₂ measurements. These phenomena may be different from those associated with the extreme points. However, in the series for patient B, Figure 2, the extremes a, b and c occur during intervals of apparent "non-randomness".

Figure 3 illustrates the distribution of PaCO₂: tc PCO₂ ratios to be experienced with this population. We suggest that while the trends in changing tc PCO₂ demonstrate shifting PaCO₂ status, a change in the ratio of paired tc PCO₂ and PaCO₂ values is the simplest bedside indicator that the aberrant physiological phenomena we have alluded to above is occurring. It is a useful *in vivo* "quality control" indicator, not in the sense of identifying error per se but in the sense of masking shifts in the relationship of measureable tissue PCO₂ to PaCO₂. A prospective study might help to identify combinations of clinical factors which change the expected tissue: blood PCO₂ status.

Contrary to our expectations, the regression studies of transcutaneous and blood PCO₂ for infants with chronic lung disease were not significantly different in r, y intercept, slope, or scatter from earlier data derived for acutely ill premature infants. The data from CLD infants did demonstrate time, dependent, non-random shifts in the tc PCO₂: PaCO₂ relationship and interinfant differences in the frequency of such phenomena. The findings are consistent with the proposition that transcutaneous PCO₂ measurements are a useful short-term trend monitor. They suggest that *in vivo* calibrations may sometimes be of limited value or misleading. The expected scatter in our comparisons of tc PCO₂ and PaCO₂ is unexplained. In view of it, we suggest that a population regression line be developed for each clinical care setting into which tc PCO₂ is introduced in order to assess the relative reliability of estimating PaCO₂ from tc PCO₂ data.

ACKNOWLEDGEMENT

We are indebted to the staff of the University Hospital Neonatal Intensive Care Unit and the technologists of our Division, especially Claudia Bfen, M.T. for their helps. Radiometer America Inc. (Cleveland, OH 44145) supported the publication costs of this manuscript.

REFERENCES

- Willard D, Eberhard P, Messer J, Erny P: Continuous noninvasive measurements of blood carbon dioxide pressure (pCO₂). In: Lauerson NH, Hochberg Hm. eds. *Clinical Perinatal Biochemical Monitoring*. Baltimore: Williams and Wilkins, 1981: 237-48.
- Hazinski TA, Severinghaus JW: Transcutaneous analysis of arterial pCO₂. *Med Instrumentation* 1982; 16: 150-3.
- Tremper KK, Shoemaker WC, Shippy CR, Nolan LS: Transcutaneous pCO₂ monitoring on adults patients in the ICU and the operating room. *Crit Care med* 1981; 9: 752-5.
- Severinghaus JW: A combined transcutaneous pO₂ — pCO₂ electrode with electrochemical HCO₃ stabilization. *J Appl Physiol* 1981; 51: 1027-32.
- Brunstler I, Enders A, Versmold HT: Skin surface pCO₂ monitoring in newborn infants in shock: Effect of hypotension and electrode temperature. *J Pediatr* 1982; 100: 454-7.
- Hansen TN, Tooley WH: Skin surface carbon dioxide tension in sick infants. *Pediatrics* 1979; 64: 942-5.
- Monaco F, McQuitty J, Nickerson BG: Calibration of

- heated transcutaneous carbon dioxide electrode to reflect arterial carbon dioxide. *Am Respir Dis* 1983; 127: 322-4.
8. Kost GJ, Chow JL, Kenny MA: Monitoring of transcutaneous carbon dioxide tension. *Am J Clin Pathol* 1983; 80: 832-8.
 9. Draper NR, Smith H: *Applied regression analysis*. John Wiley and Sons, Inc, New York, 1981: 157-62.
 10. Leary ET, Delaney CJ, Kenny MA: Use of equilibrated blood for internal blood-gas quality control. *Clin Chem* 1977; 23: 493-503.
 11. Leary ET, Graham G, Kenny MA: Commercially available blood-gas quality controls compared with tonometered blood. *Clin Chem* 1980; 26: 1309-6.
 12. Kost GJ, Chow JL, Kenny MA: Transcutaneous carbon dioxide for short-term monitoring of neonates. *Clin Chem* 1983; 28: 1543-6.
 13. Mindt W, Eberhard P, Schafer R: Monitoring of pCO₂ by skin surface sensors. *Biotelemetry Patient Monitoring* 1982; 9: 28-35.
 14. Bhat R, Kim WD, Shukla A, Vidyasager D: Simultaneous tissue pH and transcutaneous carbon dioxide monitoring in critically ill neonates. *Crit Care Med* 1981; 9: 744-9.
 15. Philip AG: Noninvasive diagnostic techniques in newborn infants. *Pediatr Clin N Am* 1982; 2: 1275-98.
 16. Severinghaus JW, Stafford M, Bradley AF: Tc pCO₂ electrode design, calibration and temperature gradient problems. *Acta Anaesthesiol Scand* 1978 (suppl); 68: 118-22.